#Tecentriq

Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.

Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.

A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.

A recent clinical trial found that the combination did not work.

Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.

Combining a custom cancer vaccine and a checkpoint inhibitor generated tumor-specific immune responses in a majority of patients.

The combination improved both overall survival and patient-reported outcomes.

Initial treatment with atezolizumab led to longer overall survival in people with high biomarker levels.

“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."

Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.

Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.